Animol Discovery
- Company typePrivate
- Founded2020
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Animol Discovery firmographics
Firmographics- Name
- Animol Discovery
- Legal name
- Animol Discovery, Inc.
- Website
- https://animol-discovery.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Animol Discovery industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Animol Discovery is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Animol Discovery business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Veterinary Pharmaceutical Pipeline: The company is building its own pipeline of proprietary veterinary small molecules and plans to advance them through clinical development. Revenue would likely come from eventual product sales or licensing agreements with larger animal health companies upon successful development and regulatory approval.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Animol Discovery product offering
Product offeringCore offering
Animol Discovery is a biopharmaceutical company that discovers and develops proprietary small molecule veterinary pharmaceuticals for companion and farm animals. The company combines genomics analysis, DNA-encoded library screening, AI/machine learning, and computational chemistry to identify novel active pharmaceutical ingredients, building a pipeline that spans antiparasitics to chronic disease treatments. Revenue is intended to come from eventual licensing of developed compounds to larger animal health companies.
Product overview
Animol Discovery operates a proprietary drug discovery platform for veterinary pharmaceuticals, combining DNA-encoded library (DEL) technology, artificial intelligence/machine learning, and computational chemistry to identify novel small molecule active pharmaceutical ingredients for companion and farm animals. The company is building its own pipeline of veterinary small molecules spanning anti-parasitics to chronic diseases, but no named commercial products have been launched yet. All discovery activities are conducted through their integrated technology platform rather than discrete product modules.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Novel drug-like compounds identified in weeks from initial DEL screen
- +1 more outcomes
Companies that use Animol Discovery
Customer profileSegments2 records
Ideal customer profiles1 record
Animol Discovery technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
Animol Discovery partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Biotechnology PartnerssupportingThe Animol team is supported by best-in-class biotechnology partners and an extensive network of industry experts and scientists for their drug discovery platform.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Animol Discovery competitors and assessment
Company assessmentBroad incumbents
- Elanco Animal Health: Major global animal health company offering parasiticides, vaccines, and therapeutics for both companion and production animals. Comparable as an incumbent acquirer with overlapping antiparasitic and chronic disease franchises and as a former employer of multiple Animol team members.
- Phibro Animal Health: Diversified animal health and mineral nutrition company with significant parasiticides, vaccines, and specialty pharmaceuticals for livestock and companion animals. Comparable as an incumbent with overlapping antiparasitic and production animal focus.
- Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company focused on companion animal therapeutics across endocrinology, dermatology, and critical care. Comparable as a mid-sized acquirer of late-stage veterinary assets and as a potential strategic partner for Animol's chronic disease programs.
- Zoetis: Largest global animal health company with a broad portfolio of veterinary pharmaceuticals, biologics, diagnostics, and parasiticides across companion and farm animals. Direct comparability as the dominant acquirer/licensee of veterinary small molecules, and home to several Animol board members and SAB contacts.
- Vimian Group: Animal health-focused specialty company with operations across pharmaceuticals, diagnostics, and medtech for veterinary markets. Comparable as an active consolidator in veterinary pharma and a plausible licensing or M&A counterparty for Animol's pipeline.
- Boehringer Ingelheim Animal Health: Top-five animal health company with leading parasiticides (e.g., NexGard) and a strong veterinary pharmaceuticals pipeline. Direct comparability as a likely licensing/strategic partner for Animol's antiparasitic and chronic disease assets.
Direct peers
- Aratana Therapeutics: Animal health biopharmaceutical company that developed novel therapeutics for companion animals before being acquired by Elanco. Direct comparability as a venture-backed veterinary biotech pursuing proprietary small molecules and biologics across similar indication areas.
- Invetx: Biotechnology company developing novel, species-specific monoclonal antibody therapeutics for animal health. Closest direct peer in terms of being a venture-backed, platform-driven animal health biotech pursuing differentiated veterinary biologics; raises and deploys capital in a comparable way to Animol.
Emerging players
- Kindeva Drug Delivery: Specialty CDMO and animal health drug developer with proprietary reformulations and combination products for veterinary use. Comparable as a development-stage animal health company turning proprietary technology into licensing transactions with larger animal health partners.
- Enko Chem: Agtech startup applying DNA-encoded library screening and AI/ML to discover safe and effective crop protection chemistries. Sister portfolio company of Anterra Capital using the same discovery playbook as Animol; provides a directly comparable model for the platform's commercial trajectory.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Animol Discovery financial estimates
Financial estimateRevenue estimate
Valuation estimate
Animol Discovery leadership team
Management profileNumber of profiles
Profiles11 records
Animol Discovery funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Animol Discovery M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Animol Discovery
What does Animol Discovery do?
Animol Discovery is a biopharmaceutical company that discovers and develops proprietary small molecule veterinary pharmaceuticals for companion and farm animals. The company combines genomics analysis, DNA-encoded library screening, AI/machine learning, and computational chemistry to identify novel active pharmaceutical ingredients, building a pipeline that spans antiparasitics to chronic disease treatments. Revenue is intended to come from eventual licensing of developed compounds to larger animal health companies.
Is Animol Discovery a public or private company?
Animol Discovery is a private company. It is classified as venture growth investor backed and is currently operating.
When was Animol Discovery founded?
Animol Discovery was founded in 2020. It employs 11 to 50 people.
Where is Animol Discovery based?
Animol Discovery is headquartered in Boston, United States, in the North America region.
How does Animol Discovery make money?
One revenue line is on record: veterinary Pharmaceutical Pipeline.
Who are Animol Discovery's main competitors?
Broad incumbents on record are Elanco Animal Health, Phibro Animal Health, Dechra Pharmaceuticals, Zoetis, Vimian Group and Boehringer Ingelheim Animal Health. Direct peers are Aratana Therapeutics and Invetx. Emerging players are Kindeva Drug Delivery and Enko Chem.
Does Animol Discovery have an API?
No public API is recorded for Animol Discovery.
What industry is Animol Discovery in?
Animol Discovery's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.